Fig. 6
Anti-cancer drug screening highlights oncogenic signaling driven by RELAFUS1 target genes. a, b Pathway enrichment analysis for RELAFUS1 target genes in 293T-RELAFUS1 (a) and H1203-mEPN (b) cells. Color nodes and the size represent the enriched gene set and the number of genes in each gene set, respectively. c Venn diagram showing the number of the overlapping of pathways involved with the 293T-RELAFUS1, 293T-RELAFUS1−S486E, and H1203-RELAFUS1 target genes. Common GO term of dysregulated pathways driven by RELAFUS1 target genes within the TSS ± 10 kb in 293T-RELAFUS1 and H1203 cells is shown in the right panel. d Correlation of cell viability in two mEPN cells (H41 and H1203). Cells were treated with 179 anti-cancer drugs with 10 μM for 72 h in two technical replicates. The mean values of two independent experiments for each cells are shown in x and y axis, respectively. Analysis was done using two-tailed Pearson's correlation. e List of twenty drugs presented over 85% growth inhibition relative to the 0.1% DMSO-treated control. The mean values of cell viability in H41 and H1203 cells are shown in the figure. f, g Cell viability of mEPN cells (f H41 and g H1203 cells) treated with six selected drugs. The IC50 values of each anti-cancer drug were shown in the figures